CytoMed Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GDTC research report →
Price Chart
About the company
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells.
- CEO
- Chee Kong Choo
- IPO
- 2023
- Employees
- 42
- HQ
- Singapore, CE, SG
Get TickerSpark's AI analysis on GDTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.93M
- P/E
- -2.28
- PEG
- -0.28
- P/S
- 16.38
- P/B
- 2.38
- EV/EBITDA
- -2.23
- Div Yield
- 0.00%
- Gross Margin
- -577.72%
- Op Margin
- -794.57%
- Net Margin
- -730.34%
- ROE
- -91.37%
- ROIC
- -97.86%
Latest fiscal year · YoY change
- Revenue
- $324.39K+366.7%
- Gross Profit
- $256.39K+389.5%
- Op Income
- $-4,789,073
- Net Income
- $-3,980,457-58.2%
- EPS
- $-0.34-54.5%
- OCF Growth
- -36.5%
- FCF Growth
- -7.1%
- 52W High
- $2.12
- 52W Low
- $0.68
- 50D MA
- $0.88
- 200D MA
- $0.97
- Beta
- 0.05
- RSI (14)
- 38
- Avg Volume
- 16.30K
No earnings-call transcripts are available for GDTC yet.
- Free Float
- 29.8%
- Shares Outstanding
- 11.83M
- Float Shares
- 3.52M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 20, 26 | Choo Chee Kong | buy | 100,000 |
| Jul 14, 26 | Choo Chee Kong | buy | 100,000 |
| Jul 20, 26 | Choo Chee Kong | buy | 100,000 |
| Jul 14, 26 | Choo Chee Kong | buy | 100,000 |
| May 13, 26 | Choo Chee Kong | buy | 112,000 |
| Mar 18, 26 | Toh Keng Kiat | other | 0 |
| Mar 18, 26 | Yew Chak Hua | other | 0 |
| Mar 18, 26 | Leong Mark Kei Wei | other | 0 |
| Mar 18, 26 | Choo Chee Kong | other | 0 |
| Mar 18, 26 | Choo Chee Kong | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GDTC coverage
Recent articles, reports, and earnings notes.
No research on GDTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GDTC report →CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 11% – Here’s What Happened
defenseworld.net · Jan 27
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why
defenseworld.net · Dec 12
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
seekingalpha.com · Oct 2
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
globenewswire.com · Oct 2
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
globenewswire.com · Aug 28
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
globenewswire.com · Aug 18
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
globenewswire.com · Jul 21
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
globenewswire.com · Apr 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.